Neuroendocrinology. 2018;106(4):312-317. doi: 10.1159/000480121. Epub 2017 Aug 19.
BACKGROUND/AIMS: Neuroendocrine neoplasms of the small intestine (SI-NENs) constitute 25-30% of all gastroenteropancreatic NEN. These tumors arise from enterochromaffin cells, and little is known about their microRNA (miRNA) expression. The purpose of this study was to characterize the expression of miRNAs in SI-NEN and to determine the potential of miRNAs as noninvasive blood-based biomarkers.
miRNA was purified from 15 tumor and 7 control tissue samples, converted to cDNA, and applied to a miScript miRNA PCR. The small nucleolar RNA, SNORD95, was used as an endogenous control.
Microarray analysis revealed 7 miRNAs that showed a promising distinction between tumorous and healthy tissue. The miRNAs miR-7-5p and miR-96-5p were clearly upregulated in the tumor compared to the healthy tissue. In contrast, miRNAs miR-9-5p, miR-122-5p, miR-124-3p, miR-143-3p, and miR-144-3p showed a distinct downregulation in the tumor compared to the healthy tissue. These results were validated on a further 15 tumor samples, and the findings held true. As the miR-7-5p was significantly upregulated and revealed a low range across tumor samples, its presence was tested in the sera of 32 tumor patients and 25 healthy controls. Sera from all patients with SI-NENs had significantly higher levels of miR-7-5p than those from the 25 healthy controls (p = 0.0002), whereas there was no correlation with age, gender, or T-stage or UICC stage.
The miRNA miR-7-5p may be a promising biomarker test for SI-NEN, which should be validated in a large-scale prospective study.
背景/目的:小肠神经内分泌肿瘤(SI-NENs)占所有胃肠胰神经内分泌肿瘤的 25-30%。这些肿瘤起源于肠嗜铬细胞,关于它们的 microRNA(miRNA)表达知之甚少。本研究的目的是描述 SI-NEN 中 miRNA 的表达,并确定 miRNA 作为非侵入性血液生物标志物的潜力。
从 15 个肿瘤和 7 个对照组织样本中纯化 miRNA,将其转化为 cDNA,并应用于 miScript miRNA PCR。小核仁 RNA,SNORD95,被用作内源性对照。
微阵列分析显示 7 个 miRNA 在肿瘤组织和健康组织之间有很好的区分。与健康组织相比,肿瘤中 miR-7-5p 和 miR-96-5p 明显上调。相比之下,miR-9-5p、miR-122-5p、miR-124-3p、miR-143-3p 和 miR-144-3p 在肿瘤组织中明显下调。这些结果在进一步的 15 个肿瘤样本中得到了验证,结果仍然成立。由于 miR-7-5p 显著上调,且在肿瘤样本中呈低范围分布,因此在 32 名肿瘤患者和 25 名健康对照者的血清中检测了其存在。所有患有 SI-NEN 的患者的血清 miR-7-5p 水平明显高于 25 名健康对照者(p = 0.0002),而与年龄、性别或 T 分期或 UICC 分期无关。
miRNA miR-7-5p 可能是一种很有前途的 SI-NEN 生物标志物检测方法,应在大规模前瞻性研究中进行验证。